Medico Remedies' bank facilities have been enhanced to Rs 42 crore by CRISIL Ratings. The agency reaffirmed stable ratings, indicating a steady credit profile despite increased borrowing capacity.
Medico Remedies Boosts Credit to Rs 42 Crore
Medico Remedies Ltd's total rated credit facilities have been enhanced to Rs 42 crore. CRISIL Ratings has reaffirmed the company's existing long-term and short-term bank facility ratings.
Reader Takeaway: Expanded credit access with stable ratings; debt management with Kotak Mahindra Bank continues.
What just happened
Medico Remedies Ltd has successfully increased its total credit facilities to Rs 42 crore. CRISIL Ratings reviewed the company's bank facilities, assigning a rating of 'Crisil BBB-/Stable' for long-term facilities (Rs 19 crore) and fund-based short-term facilities (Rs 18 crore). Non-fund-based short-term facilities received a 'Crisil A3' rating for Rs 5 crore.
Why this matters
This enhancement signifies an increased borrowing capacity for Medico Remedies, potentially supporting its operational needs and future growth. The reaffirmation of stable ratings by CRISIL suggests that the company's financial health and ability to meet its debt obligations remain sound, even with the higher credit limits.
The backstory
All the credit facilities are currently with Kotak Mahindra Bank Limited. The company has used various instruments, including Letter of Credit (Rs 5 crore) and Packing Credit (Rs 18 crore), alongside Term Loans (Rs 19 crore), all rated under the BBB- or A3 categories.
What changes now
The company now has access to a larger pool of funds for its business operations. This expansion reflects the company's ongoing financial management and its relationship with its banking partner.
Risks to watch
While the ratings are stable, investors should monitor the utilization of these enhanced credit facilities and ensure the company continues to meet its repayment obligations. Any adverse changes in the company's financial performance or the broader economic environment could impact these ratings.
Peer comparison
(No direct peer comparison data is available from the filing.)
Context metrics (time-bound)
The current ratings are valid until March 31, 2027, subject to continuous surveillance by CRISIL. The previous total rated facilities were Rs 19 crore, and have now been enhanced to Rs 42 crore.
What to track next
Investors should watch for updates on how Medico Remedies utilizes these increased credit lines and any future rating reviews or changes by CRISIL.